Zingenix: Gene Therapy for DMD
Avraham Landa, VP Business Development reports that Zingenix, previously known as ILIT Bio Ventures Ltd, a company focusing on gene therapy for severe orphan disorders including DMD(Ducehenne Muscular Dystrophy) ,using artificial transcription factors technologies, has raised a seed round of funding and has been joined by Dr. Robert Heft from Canada who has been nominated as CEO and as a member of the board of directors. Dr. Heft is a leading scientist and entrepreneur. He served as President and CEO of Enobia Pharma Inc. (Montreal, Quebec) developing therapies for the treatment of serious genetic bone disorders . In February 2012 he led the sale of Enobia to Alexion Pharmaceuticals Inc. for $1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Prior to Enobia he held several senior positions with BioMarin Pharmaceutical Inc. (Novato, California) after selling the pharmaceutical assets of IBEX Pharmaceuticals Inc. (IBT:TSX, Montreal, Quebec) to BioMarin in 2001. Zingenix Team members are : Dr. Robert Heft- CEO; Dr. Yaffa Beck- CTO; Yoram Azulai- VP Finance; Avraham Landa-VP Business Development.